Official Title
Mechanism and Immune Function Analysis of SARS-CoV-2 Infection in Hematologic Tumors and Discovery of Potential Drug Targets
Brief Summary

The goal of this observational study is to compare the immune function and infectionmechanism of patients with hematologic tumors and those people without underlyingdiseases after infection with SARS-CoV-2. Clinical characteristics, treatment options andresponses will be collected. Peripheral blood will be collected from patients withhematologic tumors infected with SARS-CoV-2 and those people without underlying diseasesinfected with SARS-CoV-2.

Detailed Description

To establish a retrospective and prospective cohort of patients with hematologic tumors
infected with SARS-CoV-2 and people without underlying diseases infected with SARS-CoV-2.
Firstly, peripheral blood samples will be collected at infection time points and after
SARS-CoV-2 nucleic acid testing turns negative. Subsequently, the transcriptome
sequencing and immunological experiments will be performed to analyze the differentially
expressed genes, immune function of cells, etc.

Comparative analysis:

1. To compare the immune function of patients with hematologic tumors and those without
underlying diseases after infection with SARS-CoV-2.

2. The transcriptomic and proteomic changes of patients with hematologic tumors are
compared with those without underlying diseases after infection with SARS-CoV-2.

3. From the perspective of complex (human protein interaction subnetwork), the dynamic
change process of SARS-CoV-2-targeted human protein complex (periodic complex) was
deeply explored, in order to further analyze its potential dynamic infection
mechanism and provide new clues for the discovery of drug targets.

Active, not recruiting
SARS-CoV-2 Infection
Hematologic Malignancy

Other: None intervention

None intervention.

Eligibility Criteria

Inclusion Criteria:

- Clinical diagnosis of hematologic tumors Clinical diagnosis of SARS-CoV-2 infection

Exclusion Criteria:

- Severe diseases associated with other systems

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
China
Locations

Peking University First Hospital
Beijing, Beijing, China

Not Provided

Peking University First Hospital
NCT Number
Keywords
SARS-CoV-2 infection
Hematologic malignancy
Leukemia
interaction
Immune Function
network analysis
MeSH Terms
Infections
Communicable Diseases
COVID-19
Neoplasms
Hematologic Neoplasms